Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

NVRO

Nevro Corp

Nov 27 • 04:00PM ET

4.58

Dollar change +0.26
Percentage change 6.02	%

Healthcare • Medical Devices • USA • NYSE

Peers: BSX MDT ABT SYK ZBH GMED PODD IART EW NNVC

| Held by: VTI IWM VXF IWN VTWO SCHA VHT IWC DFAS ETHO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.89	Insider Own	5.67%	Shs Outstand	36.36M	Perf Week	8.27%
Market Cap	181.95M	Forward P/E	-	EPS next Y	-2.53	Insider Trans	0.00%	Shs Float	35.35M	Perf Month	-12.76%
Income	-69.31M	PEG	-	EPS next Q	-0.78	Inst Own	96.35%	Short Float	7.40%	Perf Quarter	-27.76%
Sales	419.15M	P/S	0.43	EPS this Y	5.26%	Inst Trans	-5.14%	Short Ratio	4.76	Perf Half Y	-50.05%
Book/sh	7.31	P/B	0.63	EPS next Y	-4.49%	ROA	-11.98%	Short Interest	2.62M	Perf Year	-72.53%
Cash/sh	6.97	P/C	0.66	EPS next 5Y	-	ROE	-24.78%	52W Range	3.95 - 22.64	Perf YTD	-78.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.37%	ROI	-14.37%	52W High	-79.77%	Beta	0.83
Dividend TTM	-	Quick Ratio	3.76	Sales past 5Y	2.01%	Gross Margin	64.72%	52W Low	15.95%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	5.02	EPS Y/Y TTM	34.15%	Oper. Margin	-19.92%	RSI (14)	46.42	Volatility	6.50% 9.60%
Employees	1215	Debt/Eq	0.90	Sales Y/Y TTM	-0.87%	Profit Margin	-16.54%	Recom	3.47	Target Price	6.15
Option/Short	Yes / Yes	LT Debt/Eq	0.76	EPS Q/Q	36.71%	Payout	-	Rel Volume	0.62	Prev Close	4.32
Sales Surprise	4.11%	EPS Surprise	49.67%	Sales Q/Q	-6.69%	Earnings	Nov 11 AMC	Avg Volume	550.00K	Price	4.58
SMA20	-5.23%	SMA50	-8.76%	SMA200	-48.77%	Trades		Volume	343,255	Change	6.02%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-24	Upgrade	Citigroup	Sell → Neutral
Aug-08-24	Upgrade	Wolfe Research	Underperform → Peer Perform
Aug-07-24	Downgrade	Wells Fargo	Equal Weight → Underweight	$13 → $5.50
Aug-07-24	Downgrade	JP Morgan	Neutral → Underweight
Aug-07-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-22-24	Downgrade	Citigroup	Neutral → Sell	$13.50 → $9
Feb-22-24	Downgrade	Oppenheimer	Outperform → Perform
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$23 → $20
Dec-21-23	Downgrade	Canaccord Genuity	Buy → Hold	$23
Jul-19-23	Initiated	Robert W. Baird	Neutral	$26
May-31-23	Initiated	RBC Capital Mkts	Outperform	$40
May-15-23	Upgrade	Oppenheimer	Perform → Outperform	$40
Apr-14-23	Initiated	Mizuho	Neutral	$40
Jan-17-23	Downgrade	Citigroup	Buy → Neutral	$40
Jan-06-23	Downgrade	Piper Sandler	Neutral → Underweight	$42 → $38
Dec-20-22	Upgrade	Canaccord Genuity	Hold → Buy	$41 → $67
Dec-12-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$66 → $43
Oct-12-22	Initiated	Jefferies	Underperform	$31
May-05-22	Upgrade	Citigroup	Neutral → Buy	$78
Apr-13-22	Resumed	Truist	Hold	$72 → $80

Show Previous Ratings

Nov-18-24 10:00AM	Inside a $400 billion bet on the brain-computer interface revolution (Yahoo Finance) -5.09%
08:30AM	New Study Demonstrates Multiple Advantages of Nevro1, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches (PR Newswire)
Nov-15-24 08:30AM	Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (PR Newswire) +11.06%
Nov-13-24 06:23AM	Nevro secures CE mark for AI-based spinal cord stimulation system (Medical Device Network) -12.06%
Nov-12-24 01:12PM	Q3 2024 Nevro Corp Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Loading…
07:00AM	Nevro's HFX iQ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally (PR Newswire)
Nov-11-24 05:20PM	Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Nevro: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Nevro Reports Third-Quarter 2024 Financial Results (PR Newswire)
Nov-08-24 07:05AM	Nevro Corp (NVRO) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:30PM	New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy (PR Newswire) +6.92%
Oct-16-24 04:30PM	Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (PR Newswire)
Oct-10-24 04:45PM	Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 (PR Newswire)
Sep-25-24 04:12AM	Nevro obtains FDA approval for AI-based spinal cord stimulation system (Medical Device Network) -5.92%
Sep-24-24 08:00AM	Nevro Announces the Launch of HFX AdaptivAI, the Only AI-Driven Technology in Spinal Cord Stimulation (PR Newswire)
04:30PM	Loading…
Sep-19-24 04:30PM	Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (PR Newswire)
Sep-12-24 01:20AM	Vanguard Group Inc's Strategic Reduction in Nevro Corp Holdings (GuruFocus.com) +8.28%
Aug-28-24 04:15PM	Nevro to Present at Wells Fargo 2024 Healthcare Conference (PR Newswire) +10.07%
Aug-20-24 01:04PM	Here's Why You Should Retain Nevro (NVRO) Stock for Now (Zacks) -6.47%
Aug-14-24 04:30PM	Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (PR Newswire) -6.18% +12.21%
Aug-13-24 05:13PM	Engaged Capital Calls Nevro Corp. (NVRO) to Focus on Improving Profitability and Stop Pursuing Acquisitions (Insider Monkey)
Aug-09-24 08:22AM	Why Is Nevro Corp. (NVRO) a Good Buy According to Engaged Capital? (Insider Monkey) +6.00%
Aug-08-24 01:38AM	Nevro considers sale as competition for pain market ramps up (MedTech Dive) +17.39%
Aug-07-24 01:01PM	Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y (Zacks) -44.42%
Aug-06-24 05:55PM	Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:52PM	Nevro: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Nevro Reports Second-Quarter 2024 Financial Results (PR Newswire)
Jul-11-24 04:15PM	Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (PR Newswire) +9.99%
01:58PM	Here's Why You Should Retain Nevro (NVRO) Stock for Now (Zacks)
Jul-09-24 04:15PM	Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 (PR Newswire) -9.08% +5.26%
08:30AM	Loading…
Jun-28-24 08:30AM	Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (PR Newswire)
Jun-11-24 04:15PM	Nevro to Present at Truist Securities MedTech Conference (PR Newswire)
Jun-06-24 11:31AM	Why Is Nevro (NVRO) Down 8.8% Since Last Earnings Report? (Zacks)
Jun-04-24 12:37PM	Here's Why You Should Retain Nevro (NVRO) Stock for Now (Zacks)
Jun-03-24 04:13AM	Here's Why Nevro Corp. (NVRO) Shares Detracted from Performance (Insider Monkey)
May-24-24 04:15PM	Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 (PR Newswire)
May-09-24 04:05PM	Nevro to Present at BofA Securities 2024 Healthcare Conference (PR Newswire) -6.85%
May-08-24 02:57PM	Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained (MT Newswires) -11.88%
02:07PM	Nevro Corp. (NYSE:NVRO) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:14PM	Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up (Zacks)
12:12PM	Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating (MT Newswires)
11:03AM	Wells Fargo Trims Nevro Price Target to $13 From $14, Maintains Equal Weight Rating (MT Newswires)
06:56AM	Q1 2024 Nevro Corp Earnings Call (Thomson Reuters StreetEvents)
03:50AM	Nevro Corp (NVRO) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of Financial ... (GuruFocus.com)
May-07-24 09:56PM	NVRO Stock Earnings: Nevro Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:30PM	Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Nevro: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Nevro Reports First-Quarter 2024 Financial Results (PR Newswire)
Apr-17-24 08:30AM	Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024 (PR Newswire)
Mar-21-24 12:35PM	Here's Why You Should Retain Nevro (NVRO) Stock for Now (Zacks)
Feb-29-24 07:29AM	Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw (Zacks)
Feb-28-24 04:10PM	Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw (PR Newswire)
Feb-22-24 06:21PM	Why Nevro Stock Lagged the Market on Thursday (Motley Fool) -7.33%
11:20AM	Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:50AM	Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up (Zacks)
06:40AM	Q4 2023 Nevro Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-21-24 05:20PM	Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:43PM	Nevro Corp (NVRO) Reports Modest Revenue Growth Amidst Strategic Shifts (GuruFocus.com)
04:21PM	Nevro: Q4 Earnings Snapshot (Associated Press Finance)
04:06PM	Nevro Enters Into Cooperation Agreement With Engaged Capital (PR Newswire)
04:05PM	Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results (PR Newswire)
Feb-14-24 10:00AM	Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-01-24 04:30PM	Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy (PR Newswire) -5.57%
Jan-29-24 04:30PM	Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024 (PR Newswire) -5.56%
Jan-22-24 05:00AM	Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX) (News Direct)
Jan-19-24 10:48AM	Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update (Zacks)
Jan-18-24 04:15PM	Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy (PR Newswire)
Jan-17-24 04:15PM	Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting (PR Newswire)
Jan-14-24 05:28PM	Billionaire Steve Cohen Aggressively Bought These 12 Stocks Recently (Insider Monkey)
Jan-10-24 09:41AM	Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales (Zacks)
12:43AM	Nevro laying off 63 people to strengthen financial position (MedTech Dive)
Jan-09-24 08:30AM	Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results (PR Newswire)
Jan-04-24 04:15PM	Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-26-23 11:45AM	3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now (Zacks)
Dec-12-23 06:56AM	Activist investor takes stake in Nevro amid struggles to grow neuromodulation sales (MedTech Dive)
Dec-04-23 06:07AM	Nevro buys low back pain company Vyrsa for $40M (MedTech Dive)
Dec-01-23 11:31AM	Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue? (Zacks) +8.66%
11:16AM	Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment (Zacks)
Nov-30-23 05:19PM	Nevro Announces Acquisition of Vyrsa Technologies (PR Newswire)
Nov-23-23 09:55AM	Wall Street Analysts Predict a 36.66% Upside in Nevro (NVRO): Here's What You Should Know (Zacks)
Nov-21-23 09:14AM	Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment (Zacks)
Nov-20-23 07:00AM	Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain (PR Newswire)
Nov-02-23 06:33PM	Nevro Corp. (NYSE:NVRO) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.35%
12:16PM	Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up (Zacks)
08:33AM	Q3 2023 Nevro Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 07:29PM	Nevro Corp (NVRO) Q3 2023 Earnings: 3% Revenue Growth and $25.6M Net Loss from Operations (GuruFocus.com)
04:26PM	Nevro: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance (PR Newswire)
Oct-25-23 10:02AM	Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-04-23 07:00AM	Nevro to Report Third Quarter 2023 Financial Results (PR Newswire)
Sep-18-23 07:00AM	New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy (PR Newswire)
02:23AM	Heres Why Nevro Corp. (NVRO) Declined in Q2 (Insider Monkey)
Aug-23-23 07:00AM	Nevro Announces Participation in Upcoming Investor Conferences (PR Newswire)
Aug-18-23 01:01PM	Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment (Zacks)
Aug-16-23 07:00AM	New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy (PR Newswire)
Aug-15-23 10:32AM	Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment (Zacks)
Aug-10-23 04:52AM	Nevro announces launch of HFX Connect in Europe and CE marking of expanded labelling for the HFX SCS system. (PR Newswire)
Aug-02-23 03:40PM	Why Shares of Nevro Are Down Wednesday (Motley Fool) -18.69%
11:28AM	Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut (Zacks)
Aug-01-23 05:45PM	Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVRO

Nevro Corp

Upgrade your FINVIZ experience